Background. The role of amitriptyline in musculoskeletal pain is not as clearly defined as in classical neuropathic pain conditions. Objective. To assess the efficacy and effectiveness of amitriptyline in the treatment of pain in musculoskeletal complaints.
Introduction
Chronic musculoskeletal disorders are a common problem among patients visiting a general practitioner (GP). A Dutch database of GP records showed that ≥50% of the patients visited their GP with a new musculoskeletal complaint during a 10-year period (1) . In the UK, one in seven of the consultations with a GP concerned musculoskeletal complaints (2) . More importantly, these disorders are the major cause of chronic pain. A European study on the prevalence of chronic pain showed that almost 50% of the patients had back complaints and ≥40% of the patients had joint pain (3) .
The use of standard analgesics is adequate for most patients with musculoskeletal complaints, but sufficient pain relief is not always obtained. Especially patients with chronic pain may benefit from additional neuropathic pain medication. Although musculoskeletal complaints do not belong to the classic neuropathic syndromes, centrally-acting agents like antidepressants and anticonvulsants (α 2 δ-ligands) can be helpful because of the pathophysiological changes in pain processing in the central nervous system (CNS; central sensitization) described in patients with chronic pain (4) . Central sensitization can occur due to prolonged peripheral nociceptive input, which can lead to hyperexcitability of pain circuits in the CNS. A neuropathic pain component is present in 20-35% of the patients with low back pain (5, 6) and in 28-45% of patients with osteoarthritis (7) (8) (9) .
In Finland, antidepressants accounted for 1.9% of the prescriptions for musculoskeletal complaints and for 3% in the USA (10, 11) . The NICE guidelines for treatment of neuropathic pain in adults in a non-specialist setting, recommend duloxetine, amitriptyline, gabapentin and pregabalin as first choices (12), while the Dutch GP guidelines recommend amitriptyline as a first-line neuropathic agent (13) . The target points of these analgesics in the CNS differ for antidepressants and anticonvulsants (14) . We chose to focus on antidepressants; moreover, as the use of duloxetine in musculoskeletal pain is reviewed elsewhere (15, 16) , we focused on amitriptyline.
The role of amitriptyline in musculoskeletal disorders is not as well defined as in classic neuropathic pain syndromes. Therefore, the aim of this review is to assess the efficacy and effectiveness of amitriptyline in the treatment of pain in musculoskeletal complaints.
Methods

Eligibility criteria
Included in this study were randomised controlled trials (RCTs) on the use of amitriptyline for musculoskeletal disorders. Studies had to compare any dosage of amitriptyline to placebo, usual care, or standard analgesic use. We defined usual care as physiotherapy, education, other nonsurgical interventions, or 'wait and see'. Analgesics allowed as comparator were paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opiates, and other neuropathic pain medication. Moreover, corticosteroid injections were permitted as comparison. No restrictions on the duration of therapy were applied. Articles published in English, German, French, Spanish, Italian, Scandinavian or Dutch were eligible.
Outcomes of interest were pain reduction and improvement of function
Studies on fibromyalgia were excluded as these were recently evaluated in a Cochrane review (July 2015) (17) . Also excluded were RCTs evaluating the use of amitriptyline in classic neuropathic pain (e.g. diabetic polyneuropathy, HIV-associated neuropathy, post-herpetic neuralgia and phantom pain).
Search strategy
An extensive search (including Medline, Embase, Web of Science and Cochrane) up to April 2016 was made with the help of a medical librarian. The main keywords were amitriptyline and musculoskeletal complaints (see Supplementary Data Table S1 for all search terms used). In addition, references of the included articles were screened, and to find unpublished studies the Clinical Trials Search Portal (which includes ClinicalTrials.gov and the EU Clinical Trials Register amongst others) was searched.
Study selection
Two independent reviewers (JD, DS) screened the title and abstract for potentially eligible articles. Then, full articles were retrieved and assessed for eligibility. Any disagreements were resolved during a consensus meeting. If no consensus was reached, a third reviewer (SBZ) made the final decision.
Methodological quality assessment
Two independent reviewers assessed the methodological quality of the selected articles. Any disagreements were discussed in a consensus meeting. The methodological quality of the selected articles was assessed using a checklist based on the Cochrane Collaboration's tool for assessing risk of bias (18) . The following items related to the risk of bias were scored: (i) selection bias (random sequence generation and allocation concealment), (ii) performance bias (blinding participants and care providers), (iii) detection bias (blinding outcome assessors), (iv) attrition bias (drop-out rates, number of participants analysed in the group of allocation), (v) reporting bias (selective reporting) and (vi) other bias (comparability of study groups at baseline, co-interventions and compliance to treatment).
Each item on the checklist was rated as 'Yes' (indicating low risk of bias), 'No' (Indicating high risk of bias) or 'Unclear' (indicating unclear, or unknown risk of bias). We defined studies with a low risk of bias on the items 'allocation concealment' and 'participants analysed in the group of allocation', as being studies with a low risk of bias. These two items can affect our outcomes of interest (reducing pain and improvement of function) the most (19) . Blinding of outcome assessors is less important, since in most studies two active treatments are compared.
Data extraction
Data extraction was performed by two reviewers using a standardised form. Disagreements were resolved during a consensus meeting. For each article we extracted data using the PICO approach.
• 'Participants': complaint, duration of the complaint, mean age of the patients, clinical setting and baseline pain intensity.
• 'Interventions': dosage of amitriptyline, duration of the treatment.
• 'Comparison': to placebo, usual care or analgesic use.
• 'Outcomes': pain reduction, improvement of function adverse events and loss to follow-up (when mentioned).
Results
Study selection
The initial search yielded 3816 articles; after removing duplicates, 2066 articles remained. No potentially eligible studies were identified by searching for unpublished literature. After screening the title and abstract, the full-texts of 24 articles were assessed for eligibility. Finally, seven articles were included in this review ( Figure 1 ).
Study characteristics
The characteristics of the included studies (all RCTs) are presented in Table 1 . Four studies evaluated amitriptyline in low back pain; three in chronic low back pain (CLBP) (20) (21) (22) and one in acute low back pain (ALBP) (23) . One study examined amitriptyline in persistent arm pain due to repetitive use (24) . Another two studies assessed the use of amitriptyline in rheumatoid arthritis (RA) (25, 26) . Only one study on CLBP reported whether a neuropathic pain component was present; of the 200 patients, 95 had backache with radiculopathy (22) . Amitriptyline was compared with different interventions. CLBP studies compared amitriptyline with buproprione (20), fluoxetine (21) or pregabalin (22) . For ALBP, amitriptyline was compared with paracetamol (23) . In persistent arm pain (24) and one study on RA (26), amitriptyline was compared with placebo. The second study on RA evaluated the use of amitriptyline in comparison to placebo, desipramine and trazodone; this study had a cross-over design in which patients received all four interventions (25) . Dosage of amitriptyline ranged from 25 mg/day for persistent arm pain to a maximum of 150 mg/day for ALBP and CLBP. All studies were conducted in secondary and tertiary care centres. In the study on repetitive arm pain, patients were also recruited through advertisements (24) .
In all studies, primary outcome was the reduction of pain. In five studies pain was measured with a 10-point Visual Analogue Scale (VAS) or a 0-10 Numeric Rating Scale (NRS) (21) (22) (23) (24) (25) . The trial on RA [comparing amitriptyline with multiple interventions (cross-over design)] also evaluated pain on a 0-5 intensity scale in addition to the VAS (25) . The study on RA (with a placebo as comparator) measured pain on a 5-point scale (26) . The study on CLBP (comparing amitriptyline with bupropione) did not report which method was used to evaluate pain (20) .
The secondary outcome, improvement of function, was reported in two studies (22, 24) . The study on persistent arm pain evaluated arm function using the Upper Extremity Function Scale (UEFS); the total score ranges from 8-80, with higher scores indicating greater disability (27) . The study on CLBP (comparing amitriptyline with pregabalin) reported on function using the Oswestry Disability Index (ODI); this score ranges from 0-100% with a higher percentage indicating more impairment (28) . Follow-up ranged from 5-32 weeks. Table 2 shows the risk of bias for each study. Two studies had a low risk of bias (22, 24) , and 5 studies did not report on the allocation of treatment or intention-to-treat analysis (20, 21, 23, 25, 26) .
In the present study, the reviewers agreed on 78% of the items scored (Cohen's kappa 0.75).
Effectiveness: improvement of pain
One study with low risk of bias found a significant improvement of pain in the amitriptyline group between baseline and follow-up, and between the treatment groups, in favour of amitriptyline (Table 3 ) (22) . In this study on CLBP, 50 mg/day of amitriptyline reduced pain by 3.9 points (VAS 0-10), while 600 mg/day of pregabalin reduced pain by 2.9 points (VAS 0-10). Two studies, one on CLBP (20) and one on ALBP (23), found a significant improvement of pain with amitriptyline between baseline and follow-up; however, these studies found no difference between amitriptyline and bupriopione or paracetamol, respectively. In CLBP, treatment with 150 mg/day amitriptyline resulted in a pain score ≤2 in 50% of the patients, while at study start only 25% had a pain score ≤5 (20) . In ALBP, 5 weeks of treatment with 150 mg/day of amitriptyline reduced pain by 4.83 points (VAS) (23) .
The trial with the crossover design examining the effect of amitriptyline in comparison to different treatments, found that amitriptyline led to a significantly greater reduction in pain compared with baseline, placebo, trazodone or desipramine (on a 0-5 pain scale); however, no significant differences were found in pain reduction between the treatments when using the VAS (25) .
Effectiveness: improvement of function
Two studies, both with a low risk of bias, reported on improvement of function (22, 24) . Both studies found a significant increase at the end of treatment, but they compared amitriptyline with a different treatment (Table 3) . Amitriptyline let to a significant improvement in arm function in patients with persistent arm pain compared with placebo, i.e. the Upper Extremity Function Scale (UEFS (8-80) (27) improved by 3.9 points compared to 0.8 points in the placebo group (24) .
In CLBP, 65% of the patients in the amitriptyline group showed an improvement in the Oswestry Disability Index (ODI (by ≥20%; 10 points) compared to 49.5% of the patients in the pregabalin group (P = 0.03) (22) . In absolute improvement of function no significant difference was found between the two different treatments.
Side-effects
No serious side-effects were reported in any of the studies. Adverse events occurred in all treatment groups and the prevalence of side-effects was relatively high. In 6 RCTs no significant difference was found between amitriptyline and the comparator. In the study on arm pain due to repetitive use, significantly more side-effects occurred in the amitriptyline group at the midpoint of the treatment period (after 3 weeks); however, this difference had disappeared by the end of the treatment period (after 6 weeks) (24) . In the crossover trial on RA, patients reported significantly more side-effects during treatment with amitriptyline than with a placebo or trazodone. These side-effects did not lead to dose reductions (25) . Frequently occurring side-effects during amitriptyline use were drowsiness, dry mouth and constipation (Table 4) .
Discussion
Summary
This systematic review assessed the effectiveness of amitriptyline in musculoskeletal complaints. We found four studies on amitriptyline in LBP, one on amitriptyline in persistent arm pain and two studies on RA. Overall, one study on CLBP (22) with low risk of bias found a significant improvement of pain with amitriptyline compared with pregabalin. Two studies with low risk of bias found a significant improvement of function when comparing amitriptyline with pregabalin in CLBP, or placebo in persistent arm pain (22, 24) . In CLBP, the effect on function is regarded as clinically relevant since the minimal clinically important difference of the Oswestry Disability Index (ODI) ranges from 6-11 points (28-32). In absolute improvement of function no significant difference was found between amitriptyline and pregabalin, though the clinically relevant difference occurred significantly more often with treatment with amitriptyline compared with pregabalin. This clinically important difference is not as clearly defined for the Upper Extremity Function Scale (UEFS), but the improvement with amitriptyline compared to placebo is small. Overall, a similar amount of side-effects occurred in patients treated with amitriptyline and in patients treated with other analgesics; however, the prevalence of side-effects was relatively high in all studies. In chronic arm pain, patients reported more side-effects (especially drowsiness) after 3 weeks of treatment, which diminished by the end of the study period. This type of pattern is known for amitriptyline (33) .
Strengths and limitations
Although we aimed to study the role of amitriptyline in musculoskeletal complaints in general, most of the included studies investigated the role of amitriptyline in LBP. Only one study investigated its use in chronic pain due to repetitive arm use, and two trials in RA. No studies were found for osteoarthritis, another condition in which central sensitization is reported (34, 35) . Much research on amitriptyline in musculoskeletal complaints has been performed in patients with fibromyalgia; however, we excluded these studies because a Cochrane review on this topic was recently published (17) . This latter review reported that there is no unbiased evidence for the effect of amitriptyline in fibromyalgia, but there is also no good evidence for a lack of effect of amitriptyline in fibromyalgia (17) .
In some of the patients with musculoskeletal pain, central sensitization is thought to be present (5-9) and it may be expected that these patients have a better response to a centrally acting agent such as amitriptyline (4) . Only one of the included studies in our review investigated whether the presence of a neuropathic pain component (22); the authors found no significant differences in the results. Another limitation of the present review is the clinical heterogeneity of the included studies. Although all studies investigated the use of amitriptyline in musculoskeletal complaints, different conditions were evaluated. Moreover, amitriptyline was compared with a different treatment in each study, and the dosage of paracetamol was suboptimal at 2000 mg/day (23) . Furthermore, dosages of amitriptyline ranged from 25-150 mg/day. Although, in the studies in which amitriptyline showed a significant improvement of pain and/or function compared with the comparator, the dosage of amitriptyline was 25 mg/day or 50 mg/day. These are the same dosages frequently prescribed in patients with fibromyalgia (17), a condition in which central sensitization is known to occur (14) .
Another limitation of the included studies is the relatively short follow-up period. In chronic pain it is advised to evaluate the effect of an analgesic after 12 weeks of treatment. Only one of the included studies treated patients for ≥12 weeks (14 weeks) (22) . A longer treatment period could lead to more robust findings compared with a shorter treatment period.
Moreover, the studies in this review were conducted in relatively young patients; i.e. the mean age was ≤40 years in three studies (20, 23, 24) and was 41.5 years in one study (22) , while the incidence of musculoskeletal increases with age and these conditions are especially troublesome in patients aged ≥50 years (36, 37) . Also, pain processing changes with increasing age. In elderly people endogenous pain inhibition (conditioned pain modulation) functions poorly (e.g. the lack of descending analgesia). Furthermore, temporal summation of heat pain may be enhanced in older people (38, 39) . Both the lack of endogenous pain inhibition and enhanced temporal summation are known to occur in central sensitization (4, 40) . Therefore, amitriptyline might be more effective in older patients. On the other hand, side-effects may be more common in the elderly due to comorbidities, age-related physiological changes, and polypharmacy (41, 42) .
Comparison with the literature
Multiple systematic reviews have been published on the use of antidepressants in CLBP (43) (44) (45) (46) (47) . However, none of the studies included in our review was included in these earlier reviews. These reviews evaluated tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs); they found conflicting results on the use of antidepressants for CLBP, two reviews found no evidence for the use of antidepressants (43, 46) , while three found some evidence (44, 45, 47) . Pooled analyses for TCAs showed also contradictory results: Staiger et al. found a significant decrease of pain with TCAs (47) while two other reviews (including a Cochrane review) found no decrease of pain (43, 46) . However, the conclusions of these reviews should be interpreted with caution due to the diversity of the included studies and different pooling methods used (48) . Furthermore, different antidepressants with different affinities for receptors were used and these antidepressants may have different analgesic properties (48) . More recent studies with larger samples sizes investigating the use of duloxetine for CLBP show a benefit of treatment with duloxetine, although most of these studies were sponsored by the pharmaceutical industry (49) (50) (51) .
The use of antidepressants in RA was evaluated in a Cochrane review and concluded that no reliable statement could be made on the use of antidepressants in RA with the current level of evidence (52) .
Our review found results similar to the previous reviews; due to the clinical heterogeneity of our included studies it was not possible to perform a meta-analysis; this makes it difficult to draw conclusions about the benefit of amitriptyline. Moreover, we did not include the study by Pheasant et al. (53) , a study frequently included in other systematic reviews on CLBP, because it did not report on our primary outcome measurement. 
Conclusions
This systematic review assessed the use of amitriptyline in musculoskeletal complaints. While the rationale for prescribing amitriptyline in chronic musculoskeletal complaints is present in other conditions (34), we only found studies on LBP, persistent arm pain and RA. Despite the few studies, the heterogeneity and the short period of treatment, amitriptyline may improve pain and function in patients with musculoskeletal complaints. However, amitriptyline may not result in a significantly greater improvement of pain compared with other analgesics. More research is needed to establish whether and for which patients amitriptyline may be more effective than other analgesics.
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